113 related articles for article (PubMed ID: 8813479)
1. The role of surgery in patients with advanced midgut carcinoid tumours.
Ahlman H
Digestion; 1996; 57 Suppl 1():86-7. PubMed ID: 8813479
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction.
Wängberg B; Westberg G; Tylén U; Tisell L; Jansson S; Nilsson O; Johansson V; Scherstén T; Ahlman H
World J Surg; 1996 Sep; 20(7):892-9; discussion 899. PubMed ID: 8678968
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
4. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.
Kölby L; Persson G; Franzén S; Ahrén B
Br J Surg; 2003 Jun; 90(6):687-93. PubMed ID: 12808615
[TBL] [Abstract][Full Text] [Related]
5. Management of disseminated midgut carcinoid tumours.
Ahlman H; Wängberg B; Jansson S; Stenqvist O; Geterud K; Tylén U; Caidahl K; Scherstén T; Tisell LE
Digestion; 1991; 49(2):78-96. PubMed ID: 1724766
[TBL] [Abstract][Full Text] [Related]
6. Embolisation therapy in the midgut carcinoid syndrome: just tumour ischaemia?
Wängberg B; Geterud K; Nilsson O; Jansson S; Dahlström A; Tylén U; Ahlman H
Acta Oncol; 1993; 32(2):251-6. PubMed ID: 7686767
[TBL] [Abstract][Full Text] [Related]
7. Efficient symptomatic control of carcinoid tumors with somatostatin in patients with disease progression under alpha-interferon therapy.
Boehme MW; Schmidt-Gayk H; Bihl H; Eisenhut M; Herfarth CH; Kommere B; Raeth U
Hepatogastroenterology; 1995; 42(6):1053-61. PubMed ID: 8847018
[TBL] [Abstract][Full Text] [Related]
8. Circulating markers of prognosis and response to treatment in patients with midgut carcinoid tumours.
Turner GB; Johnston BT; McCance DR; McGinty A; Watson RG; Patterson CC; Ardill JE
Gut; 2006 Nov; 55(11):1586-91. PubMed ID: 16556667
[TBL] [Abstract][Full Text] [Related]
9. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
10. [Carcinoid tumors].
Tóth M; Prónai L; Németh AM; Tulassay Z
Orv Hetil; 2002 May; 143(19 Suppl):1087-92. PubMed ID: 12063867
[TBL] [Abstract][Full Text] [Related]
11. Treatment of liver metastases of carcinoid tumors.
Ahlman H; Westberg G; Wängberg B; Nilsson O; Tylén U; Scherstén T; Tisell LE
World J Surg; 1996 Feb; 20(2):196-202. PubMed ID: 8661817
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor imaging: predictive and prognostic considerations.
Anthony LB; Martin W; Delbeke D; Sandler M
Digestion; 1996; 57 Suppl 1():50-3. PubMed ID: 8813470
[TBL] [Abstract][Full Text] [Related]
13. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours.
Kinney MA; Warner ME; Nagorney DM; Rubin J; Schroeder DR; Maxson PM; Warner MA
Br J Anaesth; 2001 Sep; 87(3):447-52. PubMed ID: 11517130
[TBL] [Abstract][Full Text] [Related]
14. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
[TBL] [Abstract][Full Text] [Related]
15. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
16. Octreotide exerts only acute, but no sustained, effects on MRI enhancement of liver metastases in carcinoid syndrome.
Zomerhuis MT; Hussain SM; Feelders RA; van der Lely AJ; de Herder WW
Neuroendocrinology; 2005; 82(1):41-8. PubMed ID: 16391492
[TBL] [Abstract][Full Text] [Related]
17. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal carcinoid tumors: diagnosis and treatment.
Stamatakos M; Kontzoglou K; Sargedi C; Tsaknaki S; Iannescu R; Safioleas C; Kaitanidi V; Safioleas M
Chirurgia (Bucur); 2010; 105(6):759-66. PubMed ID: 21351698
[TBL] [Abstract][Full Text] [Related]
19. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
20. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
Massimino K; Harrskog O; Pommier S; Pommier R
J Surg Oncol; 2013 Jun; 107(8):842-6. PubMed ID: 23592524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]